DePuy Synthes, the orthopaedics company of Johnson & Johnson MedTech together with Ethicon, the Surgical Technologies Company of Johnson & Johnson MedTech are delighted to preview their plans for the 2022 British Orthopaedic Association Congress.
The 2022 BOA Annual Congress will take place on 20th - 23rd September 2022 and will focus on the theme of ‘Technology, Data and Recovery’, with four days of lectures, debates, and discussions including three days of exhibition being held at the ICC, Birmingham. Full details about the event can be found here.
The British Orthopaedic Association Congress is something we look forward to every year, it is a unique opportunity for clinical and non-clinical healthcare professionals to speak to representatives and industry experts about new developments, new products, and technological solutions alongside the always impressive scientific programme.
This year, the DePuy Synthes & Ethicon Congress booth will be our central hub of information where delegates can experience live demonstrations and expert sessions across surgical specialties including Knee, Hip, Trauma, Spine, Sports Medicine, Shoulder, Services & Solutions & General Surgery.
Andrew Dalton, DePuy Synthes’ General Manager in Great Britain, commented that “There are significant challenges across the orthopaedic care continuum as the NHS tackles the elective care backlog, we are committed to partnering with the NHS and healthcare groups to collectively meet the needs of the health care system in the UK. The combination of innovation, technology, and data insights to enhance recovery with improved outcomes is something that DePuy Synthes is committed to advancing across the entire continuum of care.
At the BOA Annual Congress 2022, we are excited to share developments from our range of solutions such as the Short Stay Programme for Hip and Knee replacement patients, KINCISE™ Surgical Automated System used in Total Hip Arthroplasty, VELYS™ Hip Navigation for implant selection and positioning as well as VELYS™ Patient Path, a personalised care platform designed to help connect teams and patients from surgery readiness through to recovery.”
For everyone in attendance at #BOA2022, we would encourage you to join us on stand #25 at any time during the Congress. For anyone who is unable to join but would like to hear about the information shared during the event, please reach out to us here and we’ll be in touch
About DePuy Synthes
DePuy Synthes is the orthopaedics company of Johnson & Johnson MedTech. With one of the most comprehensive orthopaedics portfolios in the world, we help heal and restore movement for millions of patients. Our products span various specialties, including joint reconstruction, trauma, craniomaxillofacial, spinal surgery, and sports medicine.
Building on our proud legacy of industry firsts, we are honouring our commitments to quality and innovation while creating a future where it's easier than ever before to keep people moving.
At Ethicon, a Johnson & Johnson MedTech company, putting humanity at the core of care is our passion and our purpose. In collaboration with clinicians and health care experts around the world, we develop clinically differentiated surgical technologies and solutions to help address some of the most pressing health challenges of our time such as metabolic disease, cardiovascular disease and cancer. Through our efforts and ingenuity, we aspire to elevate standards of care and create a healthier future for the patients of today and tomorrow. Reimagining how we heal.
About Johnson & Johnson MedTech:
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.